NCT04675294: Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
- State
- Under way
- Phase
- Phase 2
- People
- 189 taking part
- Started
- 2 Apr 2021
- Primary completion
- 3 Mar 2025
- Arms
- evorpacept (ALX148) + pembrolizumab
- Results
- None posted
- 19 Dec 2020: Trial registered
- 2 Apr 2021: Trial started